Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant expansion for the company in the Hong Kong market, enhancing its competitiveness in the biopharmaceutical industry [1] Group 1: Company Developments - The stock price of Dechra Pharmaceuticals-B (德琪医药-B) increased by approximately 6%, reaching HKD 4.34, with a trading volume of HKD 9.4944 million [1] - The approved applications are for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation) [1] Group 2: Industry Implications - The approval signifies the company's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical sector [1] - The introduction of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitive position in the biotechnology industry [1]
德琪医药-B涨近6% 希维奥两项补充新药申请获香港卫生署批准